Amgen Terminates Drug Trial After Failure

Thousand Oaks-based Amgen said late Wednesday that it has terminated a Phase 3 study of a drug it is developing to treat metastatic pancreatic cancer, after a recommendation by the independent committee overseeing the trial. The firm said the termination came, after the committee found that the company's ganitumab (AMG 479) compound was "unlikely to demonstrate a statistically significant improvement" in survival for patients.